Esophageal Cancer
Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers
Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.
Pembrolizumab regimen superior to chemotherapy alone in advanced esophageal cancer
The addition of pembrolizumab to chemotherapy improved OS, PFS and objective response rates among patients with untreated, advanced esophageal and esophagogastric junction adenocarcinoma, results of the phase 3 KEYNOTE-590 study showed.
FDA grants orphan drug designation to KN046 for thymic epithelial tumors
The FDA granted orphan drug designation to KN046 for the treatment of patients with thymic epithelial tumors, according to a manufacturer-issued press release.
Pembrolizumab regimen extends survival in advanced esophageal cancer
The addition of pembrolizumab to first-line chemotherapy extended OS and PFS among patients with locally advanced or metastatic esophageal cancer, according to the agent’s manufacturer.
Gum disease linked to higher risk for gastric, esophageal cancers
A history of gum disease appeared associated with significantly elevated risks for two types of gastrointestinal cancer, according to prospective study results published in Gut.
Esophageal cancer: Endoscopic therapy bests esophagectomy
Black patients less likely to undergo surgery for esophageal cancer
Black patients with esophageal cancer had a lower likelihood of receiving surgical intervention for resectable disease than their white counterparts, according to results of a retrospective study published in Journal of Gastrointestinal Surgery.
FDA approves Opdivo for advanced esophageal cancer after chemotherapy
The FDA approved nivolumab for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after receiving fluoropyrimidine- and platinum-based chemotherapy.
Proton therapy reduces toxicity risk vs. IMRT in locally advanced esophageal cancer
Proton beam therapy appeared to reduce the risk for and severity of adverse events compared with intensity-modulated radiation therapy for patients with locally advanced esophageal cancer, according to results of a randomized phase 2B study published in Journal of Clinical Oncology.
Blood test detects dozens of cancer types, often before symptoms emerge
A novel blood test accurately detected more than 50 types of cancer with a specificity of 99.3%, according to results of the prospective Circulating Cell-free Genome Atlas study published in Annals of Oncology.